Methods to design and synthesize antibody-drug conjugates (ADCs)

International Journal of Molecular Sciences

Volumn 17, Issue 2, 2016, Pages

  Yao, Houzong ^a   Jiang, Feng ^a,b   Lu, Aiping ^a   Zhang, Ge ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b NINGBO UNIVERSITY   (China)

Author keywords

Antibody drug conjugates (ADCs); Drugs; Linkers; Monoclonal antibodies (mAbs); Targeted therapy

Indexed keywords

5,5' DITHIOBIS(2 NITROBENZOIC ACID); 6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; ALCOHOL DERIVATIVE; ALDEHYDE DERIVATIVE; AMINE; AMINO ACID TRANSFER RNA LIGASE; ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; AZIDE; BRENTUXIMAB VEDOTIN; CARBAMIC ACID DERIVATIVE; DITHIOARYL PYRIDAZINEDIONE; GEMTUZUMAB OZOGAMICIN; MALEIMIDE; PACLITAXEL; PARA AMINOBENZYL CARBAMATE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PYRIDAZINE DERIVATIVE; SIALIC ACID; SODIUM 4 ((4 (CYANOETHYNYL)BENZOYL)OXY) 2,3,5,6 TETRAFLUOROBENZENESULFONATE; SORTASE; SULFONIC ACID DERIVATIVE; THIOL DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; TRIFLUOROACETIC ACID; UNCLASSIFIED DRUG; VEDOTIN; ANTINEOPLASTIC AGENT; CROSS LINKING REAGENT; MONOCLONAL ANTIBODY;

DRUG CONJUGATION; DRUG DESIGN; HODGKIN DISEASE; REVIEW; TRANSAMINATION; ANIMAL; CHEMISTRY; HUMAN;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CROSS-LINKING REAGENTS; DRUG DESIGN; HUMANS; IMMUNOCONJUGATES;

EID: 84956912894     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17020194     Document Type: Review

References (87)

1. Lenoir, T. A magic bullet: Research for profit and the growth of knowledge in Germany around 1900. Minerva 1988, 26, 66–88. [CrossRef].
2. Laurent, D.; Bernhard, S. Antibody-drug conjugates: Linking cytotoxic payloads to monoclonal antibodies. Bioconjug. Chem. 2010, 21, 5–13.
3. Perez, H.L.; Cardarelli, P.M.; Deshpande, S.; Gangwar, S.; Schroeder, G.M.; Vite, G.D.; Borzilleri, R.M. Antibody-drug conjugates: Current status and future directions. Drug Discov. Today 2014, 19, 869–881. [CrossRef] [PubMed].
4. Chari, R.V.J.; Miller, M. L.; Widdison, W.C. Antibody-drug conjugates: An emerging concept in cancer therapy. Angew. Chem. Int. Ed. Engl. 2014, 53, 3796–3827. [CrossRef] [PubMed].
5. Thudium, K.; Bilic, S.; Leipold, D.; Mallet, W.; Kaur, S.; Meibohm, B.; Erickson, H.; Tibbitts, J.; Zhao, H.; Gupta, M. American association of pharmaceutical scientists national biotechnology conference short course: Translational challenges in developing antibody-drug conjugates. MAbs 2013, 5, 5–12. [CrossRef].
6. Sievers, E.L.; Senter, P.D. Antibody-drug conjugates in cancer therapy. Annu. Rev. Med. 2013, 64, 15–29. [CrossRef] [PubMed].
7. Harper, J.; Mao, S.; Strout, P.; Kamal, A. Selecting an optimal antibody for antibody-drug conjugate therapy: Internalization and intracellular localization. Methods Mol. Biol. 2013, 1045, 41–49. [PubMed].
8. Bander, N.H. Antibody-drug conjugate target selection: Critical factors. Methods Mol. Biol. 2013, 1045, 29–40. [PubMed].
9. Gerber, H.-P.; Koehn, F.E.; Abraham, R.T. The antibody-drug conjugate: An enabling modality for natural product-based cancer therapeutics. Nat. Prod. Rep. 2013, 30, 625–639. [CrossRef] [PubMed].
10. Chudasama, V.; Maruani, A.; Caddick, S. Recent advances in the construction of antibody–drug conjugates. Nat. Chem. 2016, 8, 114–119. [CrossRef].
11. Diamantis, N.; Banerji, U. Antibody-drug conjugates—An emerging class of cancer treatment. Br. J. Cancer 2016. [CrossRef] [PubMed].
12. McAuley, A.; Jacob, J.; Kolvenbach, C.G.; Westland, K.; Lee, H.J.; Brych, S.R.; Rehder, D.; Kleemann, G.R.; Brems, D.N.; Matsumura, M. Contributions of a disulfide bond to the structure, stability, and dimerization of human IgG1 antibody CH3 domain. Protein Sci. 2008, 17, 95–106. [CrossRef] [PubMed].
13. Sun, M.M.C.; Beam, K.S.; Cerveny, C.G.; Hamblett, K.J.; Blackmore, R.S.; Torgov, M.Y.; Handley, F.G.M.; Ihle, N.C.; Senter, P.D.; Alley, S.C. Reduction–alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug. Chem. 2005, 16, 1282–1290. [CrossRef] [PubMed].
14. Willner, D.; Trail, P.A.; Hofstead, S.J.; King, H.D.; Lasch, S.J.; Braslawsky, G.R.; Greenfield, R.S.; Kaneko, T.; Firestone, R.A. (6-Maleimidocaproyl) hydrazone of doxorubicin-a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjug. Chem. 1993, 4, 521–527. [CrossRef] [PubMed].
15. Doronina, S.O.; Toki, B.E.; Torgov, M.Y.; Mendelsohn, B.A.; Cerveny, C.G.; Chace, D.F.; DeBlanc, R.L.; Gearing, R.P.; Bovee, T.D.; Siegall, C.B.; et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 2003, 21, 778–784. [CrossRef].
16. Francisco, J.A.; Cerveny, C.G.; Meyer, D.L.; Mixan, B.J.; Klussman, K.; Chace, D.F.; Rejniak, S.X.; Gordon, K.A.; DeBlanc, R.; Toki, B.E.; et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003, 102, 1458–1465. [CrossRef] [PubMed].
17. Hamblett, K.J.; Senter, P.D.; Chace, D.F.; Sun, M.M.C.; Lenox, J.; Cerveny, C.G.; Kissler, K.M.; Bernhardt, S.X.; Kopcha, A.K.; Zabinski, R.F.; et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 2004, 10, 7063–7070. [CrossRef] [PubMed].
18. McDonagh, C.F.; Turcott, E.; Westendorf, L.; Webster, J.B.; Alley, S.C.; Kim, K.; Andreyka, J.; Stone, I.; Hamblett, K.J.; Francisco, J.A.; et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Prot. Eng. Des. Sel. 2006, 19, 299–307. [CrossRef] [PubMed].
19. Andersen, D.C.; Reilly, D.E. Production technologies for monoclonal antibodies and their fragments. Curr. Opin. Biotechnol. 2004, 15, 456–462. [CrossRef] [PubMed].
20. Schroeder, D.D.; Tankersly, D.L.; Lundblad, J.L. A new preparation of modified immune serum globulin (human) suitable for intravenous administration. I. Standardization of the reduction and alkylation reaction. Vox. Sang. 1981, 40, 373–382. [CrossRef] [PubMed].
21. Liu, H.; Chumsae, C.; Gaza-Bulseco, G.; Hurkmans, K.; Radziejewski, C.H. Ranking the susceptibility of disulfide bonds in human IgG1 antibodies by reduction, differential alkylation, and LC-MS analysis. Anal. Chem. 2010, 82, 5219–5226. [CrossRef].
22. Nwe, K.; Milenic, D.E.; Ray, G.L.; Kim, Y.-S.; Brechbiel, M.W. Preparation of cystamine core dendrimer and antibody_dendrimer conjugates for MRI angiography. Mol. Pharm. 2012, 9, 374–381. [CrossRef] [PubMed].
23. Nanaware-Kharade, N.; Gonzalez, G.A.; Lay, J.O.; Hendrickson, H.P.; Peterson, E.C. Therapeutic anti-methamphetamine antibody fragment-nanoparticle conjugates: Synthesis and in vitro characterization. Bioconjug. Chem. 2012, 23, 1864–1872. [CrossRef] [PubMed].
24. Hermanson, G.T. Bioconjugate Techniques, 2nd ed.; Academic Press: New York, NY, USA, 2008; pp. 1041–1132.
25. Gauthier, M.A.; Klok, H.-A. Peptide/protein-polymer conjugates: Synthetic strategies and design concepts. Chem. Commun. 2008, 21, 2591–2611. [CrossRef] [PubMed].
26. Shen, B.-Q.; Xu, K.; Liu, L.; Raab, H.; Bhakta, S.; Kenrick, M.; Parsons-Reponte, K.L.; Tien, J.; Yu, S.-F.; Mai, E.; et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat. Biotechnol. 2012, 30, 184–189. [CrossRef] [PubMed].
27. Nunes, J.P.M.; Morais, M.; Vassileva, V.; Robinson, E.; Rajkumar, V.S.; Smith, M.E.B.; Pedley, R.B.; Caddick, S.; Baker, J.R.; Chudasama, V. Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody_drug conjugate (ADC). Chem. Commun. 2015, 51, 10624–10627. [CrossRef] [PubMed].
28. Lyon, R.P.; Setter, J.R.; Bovee, T.D.; Doronina, S.O.; Hunter, J.H.; Anderson, M.E.; Balasubramanian, C.L.; Duniho, S.M.; Leiske, C.I.; Li, F.; et al. Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates. Nat. Biotechnol. 2014, 32, 1059–1062. [CrossRef] [PubMed].
29. Tumey, L.N.; Charati, M.; He, T.; Sousa, E.; Ma, D.; Han, X.; Clark, T.; Casavant, J.; Loganzo, F.; Barletta, F.; et al. Mild method for succinimide hydrolysis on ADCs: Impact on ADC potency, stability, exposure, and efficacy. Bioconjug. Chem. 2014, 25, 1871–1880. [CrossRef] [PubMed].
30. Ojima, I.; Geng, X.; Wu, X.; Qu, C.; Borella, C.P.; Xie, H.; Wilhelm, S.D.; Leece, B.A.; Bartle, L.M.; Goldmacher, V.S.; et al. Tumor-specific novel taxoid-monoclonal antibody conjugates. J. Med. Chem. 2002, 45, 5620–5623. [CrossRef] [PubMed].
31. Widdison, W.C.; Wilhelm, S.D.; Cavanagh, E.E.; Whiteman, K.R.; Leece, B.A.; Kovtun, Y.; Goldmacher, V.S.; Xie, H.; Steeves, R.M.; Lutz, R.J.; et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J. Med. Chem. 2006, 49, 4392–4408. [CrossRef] [PubMed].
32. Kolodych, S.; Koniev, O.; Baatarkhuu, Z.; Bonnefoy, J.-Y.; Debaene, F.; Cianférani, S.; Dorsselaer, A.V.; Wagner, A. CBTF: New amine-to-thiol coupling reagent for preparation of antibody conjugates with increased plasma stability. Bioconjug. Chem. 2015, 26, 197–200. [CrossRef] [PubMed].
33. Cal, P.M.; Bernardes, G.J.; Gois, P.M. Cysteine-selective reactions for antibody conjugation. Angew. Chem. Int. Ed. Engl. 2014, 53, 10585–10587. [CrossRef] [PubMed].
34. Kline, T.; Steiner, A.R.; Penta, K.; Sato, A.K.; Hallam, T.J.; Yin, G. Methods to make homogenous antibody drug conjugates. Pharm. Res. 2015, 32, 3480–3493. [CrossRef] [PubMed].
35. Badescu, G.; Bryant, P.; Bird, M.; Henseleit, K.; Swierkosz, J.; Parekh, V.; Tommasi, R.; Pawlisz, E.; Jurlewicz, K.; Farys, M.; et al. Bridging disulfides for stable and defined antibody drug conjugates. Bioconjug. Chem. 2014, 25, 1124–1136. [CrossRef] [PubMed].
36. Bryant, P.; Pabst, M.; Badescu, G.; Bird, M.; McDowell, W.; Jamieson, E.; Swierkosz, J.; Jurlewicz, K.; Tommasi, R.; Henseleit, K.; et al. In vitro and in vivo evaluation of cysteine rebridged trastuzumab-MMAE antibody drug conjugates with defined drug-to-antibody ratios. Mol. Pharm. 2015, 12, 1872–1879. [CrossRef] [PubMed].
37. Behrens, C.R.; Ha, E.H.; Chinn, L.L.; Bowers, S.; Probst, G.; Fitch-Bruhns, M.; Monteon, J.; Valdiosera, A.; Bermudez, A.; Liao-Chan, S.; et al. Antibody_drug conjugates (ADCs) derived from interchain cysteine cross-linking demonstrate improved homogeneity and other pharmacological properties over conventional heterogeneous ADCs. Mol. Pharm. 2015, 12, 3986–3998. [CrossRef] [PubMed].
38. Lee, M.T.W.; Maruani, A.; Baker, J.R.; Caddick, S.; Chudasama, V. Next-generation disulfide stapling: Reduction and functional re-bridging all in one. Chem. Sci. 2016, 7, 799–802. [CrossRef].
39. Maruani, A.; Savoie, H.; Bryden, F.; Caddick, S.; Boyle, R.; Chudasama, V. Site-selective multi-porphyrin attachment enables the formation of a next-generation antibody-based photodynamic therapeutic. Chem. Commun. 2015, 51, 15304–15307. [CrossRef] [PubMed].
40. Maruani, A.; Smith, M.E.B.; Miranda, E.; Chester, K.A.; Chudasama, V.; Caddick, S. A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy. Nat. Commun. 2015, 6, 6645. [CrossRef] [PubMed].
41. Juillerat, A.; Gronemeyer, T.; Keppler, A.; Gendreizig, S.; Pick, H.; Vogel, H.; Johnsson, K. Directed evolution of O6-alkylguanine-DNA alkyltransferase for efficient labeling of fusion proteins with small molecules in vivo. Chem. Biol. 2003, 10, 313–317. [CrossRef].
42. Cohen, R.; Vugts, D.J.; Visser, G.W.M.; Walsum, M.S.-V.; Bolijn, M.; Spiga, M.; Lazzari, P.; Shankar, S.; Sani, M.; Zanda, M.; et al. Development of novel ADCs: Conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling. Cancer Res. 2014, 74, 5700–5710. [CrossRef] [PubMed].
43. Mueller, B.M.; Wrasidlo, W.A.; Reisfeld, R.A. Determination of the number of e-amino groups available for conjugation of effect or molecules to monoclonal antibodies. Hybridoma 1988, 7, 453–456. [CrossRef] [PubMed].
44. Wakankar, A.A.; Feeney, M.B.; Rivera, J.; Chen, Y.; Kim, M.; Sharma, V.K.; Wang, Y.J. Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: Changes due to modification and conjugation processes. Bioconjug. Chem. 2010, 21, 1588–1595. [CrossRef] [PubMed].
45. Siegel, M.M.; Tabei, K.; Kunz, A.; Hollander, I.J.; Hamann, R.R.; Bell, D.H.; Berkenkamp, S.; Hillenkamp, F. Calicheamicin derivatives conjugated to monoclonal antibodies: Determination of loading values and distributions by infrared and UV matrix-assisted laser desorption/ionization mass spectrometry and electrospray ionization mass spectrometry. Anal. Chem. 1997, 69, 2716–2726. [CrossRef].
46. Adamczyk, M.; Gebler, J.; Shreder, K.; Wu, J. Region-selective labeling of antibodies as determined by electrospray ionization-mass spectrometry (ESI-MS). Bioconjug. Chem. 2000, 11, 557–563. [CrossRef].
47. Hamann, P.R.; Hinman, L.M.; Hollander, I.; Beyer, C.F.; Lindh, D.; Holcomb, R.; Hallett, W.; Tsou, H.R.; Upeslacis, J.; Shochat, D.; et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem. 2002, 13, 47–58. [CrossRef] [PubMed].
48. Feng, Y.; Zhu, Z.; Chen, W.; Prabakaran, P.; Lin, K.; Dimitrov, D. Conjugates of small molecule drugs with antibodies and other proteins. Biomedicines 2014, 2, 1–13. [CrossRef].
49. Hong, L.P.T.; Scoble, J.A.; Doughty, L.; Coia, G.; Williams, C.C. Cancer-targeting antibody-drug con jugates:Site-specific conjugation of doxorubicin to anti-EGFR 528 Fab9 through a polyethylene glycol linker. Aust. J. Chem. 2011, 64, 779–789. [CrossRef].
50. Jeger, S.; Zimmermann, K.; Blanc, A.; Grünberg, J.; Honer, M.; Hunziker, P.; Struthers, H.; Schibli, R. Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angew. Chem. Int. Ed. Engl. 2010, 49, 9995–9997. [CrossRef] [PubMed].
51. Mazmanian, S.K.; Liu, G.; Ton-That, H.; Schneewind, O. Staphylococcus aureus sortase, an enzyme that anchors surface proteins to the cell wall. Science 1999, 285, 760–763. [CrossRef] [PubMed].
52. Tsukiji, S.; Nagamune, T. Sortase-mediated ligation: A gift from Gram-positive bacteria to protein engineering. Chem. Biochem. Eur. J. Chem. Biol. 2009, 10, 787–798. [CrossRef] [PubMed].
53. Madej, M.P.; Coia, G.; Williams, C.C.; Caine, J.M.; Pearce, L.A.; Attwood, R.; Bartone, N.A.; Dolezal, O.; Nisbet, R.M.; Nuttall, S.D.; et al. Engineering of an anti-epidermal growth factor receptor antibody to single chain format and labeling by Sortase A-mediated protein ligation. Biotechnol. Bioeng. 2012, 109, 1461–1470. [CrossRef] [PubMed].
54. Ta, H.T.; Peter, K.; Hagemeyer, C.E. Enzymatic antibody tagging: Toward a universal biocompatible targeting tool. Trends Cardiovasc. Med. 2012, 22, 105–111. [CrossRef] [PubMed].
55. Williamson, D.J.; Fascione, M.A.; Webb, M.E.; Turnbull, W.B. Efficient N-terminal labeling of proteins by use of sortase. Angew. Chem. 2012, 124, 9511–9514. [CrossRef].
56. Chen, I.; Howarth, M.; Lin, W.; Ting, A.Y. Site-specific labeling of cell surface proteins with biophysical probes using biotin ligase. Nat. Methods 2005, 2, 99–104. [CrossRef] [PubMed].
57. Jeffrey, S.C.; Torgov, M.Y.; Andreyka, J.B.; Boddington, L.; Cerveny, C.G.; Denny, W.A.; Gordon, K.A.; Gustin, D.; Haugen, J.; Toni Kline, T.; et al. Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates. J. Med. Chem. 2005, 48, 1344–1358. [CrossRef] [PubMed].
58. Burke, P.J.; Senter, P.D.; Meyer, D.W.; Miyamoto, J.B.; Anderson, M.; Toki, B.E.; Manikumar, G.; Wani, M.C.; Kroll, D.J.; Jeffrey, S.C. Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues. Bioconjug. Chem. 2009, 20, 1242–1250. [CrossRef] [PubMed].
59. Dubowchik, G.M.; Firestone, R.A.; Padilla, L.; Willner, D.; Hofstead, S.J.; Mosure, K.; Knipe, J.O.; Lasch, S.J.; Trail, P.A. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: Model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug. Chem. 2002, 13, 855–869. [CrossRef] [PubMed].
60. King, H.D.; Dubowchik, G.M.; Mastalerz, H.; Willner, D.; Hofstead, S.J.; Firestone, R.A.; Lasch, S.J.; Trail, P.A. Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: Inhibition of aggregation by methoxytriethyleneglycol chains. J. Med. Chem. 2002, 45, 4336–4343. [CrossRef] [PubMed].
61. Walker, M.A.; Dubowchik, G.M.; Hofstead, S.J.; Trail, P.A.; Firestone, R.A. Synthesis of an immunoconjugate of camptothecin. Bioorg. Med. Chem. Lett. 2002, 12, 217–219. [CrossRef].
62. Elgersma, R.C.; Coumans, R.G.E.; Huijbregts, T.; Menge, W.M.P.B.; Joosten, J.A.F.; Spijker, H.J.; de Groot, F.M.H.; van der Lee, M.M.C.; Ubink, R.; van den Dobbelsteen, D.J. Design, synthesis, and evaluation of linker-duocarmycin payloads: Toward selection of HER2-targeting antibody_drug conjugate SYD985. Mol. Pharm. 2015, 12, 1813–1835. [CrossRef].
63. Moon, S.-J.; Govindan, S.V.; Cardillo, T.M.; D’Souza, C.A.; Hansen, H.J.; Goldenberg, D.M. Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. J. Med. Chem. 2008, 51, 6916–6926. [CrossRef] [PubMed].
64. Zhao, H.; Rubio, B.; Sapra, P.; Wu, D.; Reddy, P.; Sai, P.; Martinez, A.; Gao, Y.; Lozanguiez, Y.; Longley, C.; et al. Novel prodrugs of SN-38 using multiarm poly(ethylene glycol) linkers. Bioconjug. Chem. 2008, 19, 849–859. [CrossRef] [PubMed].
65. Toki, B.E.; Cerveny, C.G.; Wahl, A.F.; Senter, P.D. Protease mediated fragmentation of p-amidobenzyl ethers: A new strategy for the activation of anticancer prodrugs. J. Org. Chem. 2002, 67, 1866–1872. [CrossRef].
66. Denny, W.A. DNA minor groove alkylating agents. Curr. Med. Chem. 2001, 8, 533–544. [CrossRef] [PubMed].
67. Quiles, S.; Raisch, K.P.; Sanford, L.L.; Bonner, J.A.; Safavy, A. Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy. J. Med. Chem. 2010, 53, 586–594. [CrossRef] [PubMed].
68. Drake, P.M.; Albers, A.E.; Baker, J.; Banas, S.; Barfield, R.M.; Bhat, A.S.; de Hart, G.W.; Garofalo, A.W.; Holder, P. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes. Bioconjug. Chem. 2014, 25, 1331–1341. [CrossRef].
69. Rabuka, D.; Rush, J.S.; de Hart, G.W.; Wu, P.; Bertozzi, C.R. Site-specific chemical protein conjugation using genetically encoded aldehyde tags. Nat. Protoc. 2012, 7, 1052–1067. [CrossRef].
70. Agarwal, P.; Kudirka, R.; Albers, A.E.; Barfield, R.M.; de Hart, G.W.; Drake, P.M.; Jones, L.C.; Rabuka, D. Hydrazino-Pictet-Spengler ligation as a biocompatible method for the generation of stable protein conjugates. Bioconjug. Chem. 2013, 24, 846–851. [CrossRef].
71. Lemke, E.A. The exploding genetic code. ChemBioChem 2014, 15, 1691–1694. [CrossRef] [PubMed].
72. Kim, C.H.; Axup, J.Y.; Schultz, P.G. Protein conjugation with genetically encoded unnatural amino acids. Curr. Opin. Chem. Biol. 2013, 17, 412–419. [CrossRef] [PubMed].
73. Hutchins, B.M.; Kazane, S.A.; Staflin, K.; Forsyth, J.S.; Felding-Habermann, B.; Smider, V.V.; Schultz, P.G. Selective formation of covalent protein heterodimers with an unnatural amino acid. Chem. Biol. 2011, 18, 299–303. [CrossRef] [PubMed].
74. Axup, J.Y.; Bajjuri, K.M.; Ritland, M.; Hutchins, B.M.; Kim, C.H.; Kazane, S.A.; Halder, R.; Forsyth, J.S.; Santidrian, A.F. Synthesis of site-specific antibody–drug conjugates using unnatural amino acids. Proc. Natl. Acad. Sci. USA 2012, 109, 16101–16106. [CrossRef] [PubMed].
75. Zhou, Q.; Stefano, J.E.; Manning, C.; Kyazike, J.; Chen, B.; Gianolio, D.A.; Park, A.; Busch, M.; Bird, J. Site-specific antibody–drug conjugation through glycoengineering. Bioconjug. Chem. 2014, 25, 510–520. [CrossRef].
76. Witus, L.S.; Francis, M. Site-Specific protein bioconjugation via a pyridoxal 51-phosphate-mediated N-terminal transamination reaction. Curr. Protoc. Chem. Biol. 2010, 2, 125–134. [PubMed].
77. Kalia, J.; Raines, R.T. Hydrolytic stability of hydrazones and oximes. Angew. Chem. Int. Ed. 2008, 47, 7523–7526. [CrossRef] [PubMed].
78. Buckley, T.F.; Rapoport, H. Mild and simple biomimetic conversion of amines to carbonyl compounds. J. Am. Chem. Soc. 1982, 104, 4446–4450. [CrossRef].
79. Witus, L.S.; Netirojjanakul, C.; Palla, K.S.; Muehl, E. M.; Weng, C.-H.; Iavarone, A.T.; Francis, M.B. Site-Specific Protein Transamination Using N-Methylpyridinium-4-Carboxaldehyde. J. Am. Chem. Soc. 2013, 135, 17223–17229. [CrossRef] [PubMed].
80. Dirksen, A.; Madsen, M.; Iacono, G.D.; Matin, M.J.; Bacica, M.; Stankovic, N.; Callans, S.; Bhat, A. Parallel Synthesis and screening of peptide conjugates. Bioconjug. Chem. 2014, 25, 1052–1060. [CrossRef] [PubMed].
81. Zhou, Q.; Gui, J.; Pan, C.-M.; Albone, E.; Cheng, X.; Suh, E.M.; Grasso, L.; Ishihara, Y.; Baran, P.S. Bioconjugation by native chemical tagging of C–H bonds. J. Am. Chem. Soc. 2013, 135, 12994–12997. [CrossRef] [PubMed].
82. Griffin, M.; Casadio, R.; Bergamini, C.M. Transglutaminases: Nature’s biological glues. Biochem. J. 2002, 396, 377–396. [CrossRef] [PubMed].
83. Dennler, P.; Chiotellis, A.; Fischer, E.; Brégeon, D.; Belmant, C.; Gauthier, L.; Lhospice, F.; Romagne, F.; Schibli, R. Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody–drug conjugates. Bioconjug. Chem. 2014, 25, 569–578. [CrossRef] [PubMed].
84. Strop, P. Versatility of microbial transglutaminase. Bioconjug. Chem. 2014, 25, 855–862. [CrossRef] [PubMed].
85. Strop, P.; Liu, S.H.; Dorywalska, M.; Delaria, K.; Dushin, R.G.; Tran, T.T.; Ho, W.H.; Farias, S.; Casas, M.G.; Abdiche, Y.; et al. Location matters: Site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem. Biol. 2013, 20, 161–167. [CrossRef] [PubMed].
86. Zimmerman, E.S.; Heibeck, T.H.; Gill, A.; Li, X.; Murray, C.J.; Madlansacay, M.R.; Tran, C.; Uter, N.T.; Yin, G.; Rivers, P.J. Production of site-specific antibody–drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjug. Chem. 2014, 25, 351–361. [CrossRef] [PubMed].
87. Bryden, F.; Maruani, A.; Savoie, H.; Chudasama, V.; Smith, M.E.B.; Caddick, S.; Boyle, R.W. Regioselective and stoichiometrically controlled conjugation of photodynamic sensitizers to a HER2 targeting antibody fragment. Bioconjug. Chem. 2014, 25, 611–617. [CrossRef] [PubMed].